RESUMEN
Berberine (BBR) is a natural isoquinoline alkaloid, which is used in traditional medicine for its anti-microbial, anti-protozoal, anti-diarrhoeal activities. Berberine interacts with DNA and displays anti-cancer activities, yet its effects on cellular DNA repair and on synthetic treatments with chemotherapeutic drugs remain unclear. In this study, we investigated the effects of BBR on DNA repair and on sensitization of breast cancer cells to different types of DNA damage anti-tumoural drugs. We found BBR arrested cells in the cell cycle S phase and induced DNA breaks. Cell growth analysis showed BBR sensitized MDA-MB-231 cells to cisplatin, camptothecin and methyl methanesulfonate; however, BBR had no synergistic effects with hydroxurea and olaparib. These results suggest BBR only affects specific DNA repair pathways. Western blot showed BBR down-regulated XRCC1 expressions, and the rescued XRCC1 recovered the resistance of cancer cells to BBR. Therefore, we conclude that BBR interferes with XRCC1-mediated base excision repair to sensitize cancer cells to chemotherapeutic drugs. These finding can contribute to understanding the effects of BBR on cellular DNA repair and the clinical employment of BBR in treatment of breast cancer.
Asunto(s)
Antineoplásicos/farmacología , Berberina/farmacología , Neoplasias de la Mama/patología , Reparación del ADN/efectos de los fármacos , Proteína 1 de Reparación por Escisión del Grupo de Complementación Cruzada de las Lesiones por Rayos X/metabolismo , Camptotecina/farmacología , Puntos de Control del Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Cisplatino/farmacología , Roturas del ADN/efectos de los fármacos , Regulación hacia Abajo/efectos de los fármacos , Femenino , Humanos , Hidroxiurea/farmacología , Proteínas de Neoplasias/metabolismo , Ftalazinas/farmacología , Piperazinas/farmacología , Fase S/efectos de los fármacosRESUMEN
Pancreatic cancer is devastating cancer worldwide with few if any truly effective therapies. Pancreatic cancer has an increasing incidence and may become the second leading cause of death from cancer. Novel, more effective therapeutic approaches are needed as pancreatic cancer patients usually survive for less than a year after being diagnosed. Control of blood sugar levels by the prescription drug metformin in diseases such as diabetes mellitus has been examined in association with pancreatic cancer. While the clinical trials remain inconclusive, there is hope that certain diets and medications may affect positively the outcomes of patients with pancreatic and other cancers. Other natural compounds may share some of the effects of metformin. One "medicinal" fruit consumed by millions worldwide is berberine (BBR). Metformin and BBR both activate AMP-activated protein kinase (AMPK) which is a key mediator of glucose metabolism. Glucose metabolism has been shown to be very important in cancer and its significance is increasing. In the following studies, we have examined the effects of metformin, BBR and a panel of modified BBRs (NAX compounds) and chemotherapeutic drugs on the growth of four different human pancreatic adenocarcinoma cell lines (PDAC). Interestingly, the effects of metformin could be enhanced by BBR and certain modified BBRs. Upon restoration of WT-TP53 activity in MIA-PaCa-2â¯cells, an altered sensitivity to the combination of certain NAX compounds and metformin was observed compared to the parental cells which normally lack WT-TP53. Certain NAX compounds may interact with WT-TP53 and metformin treatment to alter the expression of key molecules involved in cell growth. These results suggest a therapeutic approach by combining certain pharmaceutical drugs and nutraceuticals to suppress the growth of cancer cells.
Asunto(s)
Berberina , Proliferación Celular/efectos de los fármacos , Metformina/uso terapéutico , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/mortalidad , Proteínas Quinasas Activadas por AMP/antagonistas & inhibidores , Proteínas Quinasas Activadas por AMP/metabolismo , Berberina/análogos & derivados , Berberina/uso terapéutico , Humanos , Proteínas de Neoplasias/antagonistas & inhibidores , Proteínas de Neoplasias/metabolismo , Neoplasias Pancreáticas/enzimología , Neoplasias Pancreáticas/patologíaRESUMEN
Mutations at the TP53 gene are readily detected (approximately 50-75%) in pancreatic ductal adenocarcinoma (PDAC) patients. TP53 was previously thought to be a difficult target as it is often mutated, deleted or inactivated on both chromosomes in certain cancers. In the following study, the effects of restoration of wild-type (WT) TP53 activity on the sensitivities of MIA-PaCa-2 pancreatic cancer cells to the MDM2 inhibitor nutlin-3a in combination with chemotherapy, targeted therapy, as well as, nutraceuticals were examined. Upon introduction of the WT-TP53 gene into MIA-PaCa-2â¯cells, which contain a TP53 gain of function (GOF) mutation, the sensitivity to the MDM2 inhibitor increased. However, effects of nutlin-3a were also observed in MIA-PaCa-2â¯cells lacking WT-TP53, as upon co-treatment with nutlin-3a, the sensitivity to certain inhibitors, chemotherapeutic drugs and nutraceuticals increased. Interestingly, co-treatment with nutlin-3a and certain chemotherapeutic drug such as irinotecan and oxaliplatin resulted in antagonistic effects in cells both lacking and containing WT-TP53 activity. These studies indicate the sensitizing abilities that WT-TP53 activity can have in PDAC cells which normally lack WT-TP53, as well as, the effects that the MDM2 inhibitor nutlin-3a can have in both cells containing and lacking WT-TP53 to various therapeutic agents.
Asunto(s)
Antineoplásicos/farmacología , Carcinoma Ductal Pancreático/metabolismo , Imidazoles/farmacología , Neoplasias Pancreáticas/metabolismo , Piperazinas/farmacología , Proteínas Proto-Oncogénicas c-mdm2/antagonistas & inhibidores , Proteína p53 Supresora de Tumor/metabolismo , Carcinoma Ductal Pancreático/tratamiento farmacológico , Carcinoma Ductal Pancreático/genética , Línea Celular Tumoral , Suplementos Dietéticos/análisis , Humanos , Irinotecán/farmacología , Oxaliplatino/farmacología , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/genética , Proteínas Proto-Oncogénicas c-mdm2/genética , Proteínas Proto-Oncogénicas c-mdm2/metabolismo , Transducción de Señal/efectos de los fármacos , Proteína p53 Supresora de Tumor/genéticaRESUMEN
Berberine (BBR) is an isoquinoline alkaloid extracted from medicinal plants such as Hydrastis canadensis, Berberis aristata and Coptis chinensis. BBR displays a number of beneficial roles in the treatment of various types of cancers, yet the precise mechanisms of its action remain unclear. Cisplatin is an effective cancer chemotherapeutic agent and functions by generating DNA damage, promoting DNA damage-induced cell cycle arrest and apoptosis; however, its efficacy is challenged by the resistance of tumor cells in clinical application. The aim of the present study was to investigate the effects of BBR in combination with cisplatin on human breast cancer cells. MTT assay showed that BBR inhibited breast cancer MCF-7 cell growth with a 50% inhibitory concentration (IC50) value of 52.178±1.593 µM and the IC50 value of cisplatin was 49.541±1.618 µM, while in combination with 26 µM BBR, the IC50 value of cisplatin was 5.759±0.76 µM. BBR sensitized the MCF-7 cells to cisplatin in a time- and dose-dependent manner. After treatment of BBR and cisplatin, the cellular pro-apoptotic capase-3 and cleaved capspase-3 and caspase-9 were upregulated and the anti-apoptotic Bcl-2 was downregulated. Importantly, BBR restrained the expression of cellular PCNA, and immunofluoresence analysis of γH2AX showed that BBR increased the DNA damages induced by cisplatin. Taken together, the results demonstrated that BBR sensitized MCF-7 cells to cisplatin through induction of DNA breaks and caspase-3-dependent apoptosis.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Apoptosis/efectos de los fármacos , Neoplasias de la Mama/tratamiento farmacológico , Caspasa 3/metabolismo , Proliferación Celular/efectos de los fármacos , Roturas del ADN/efectos de los fármacos , Antineoplásicos/administración & dosificación , Berberina/administración & dosificación , Mama/efectos de los fármacos , Mama/metabolismo , Neoplasias de la Mama/metabolismo , Caspasa 9/metabolismo , Línea Celular Tumoral , Cisplatino/administración & dosificación , Regulación hacia Abajo/efectos de los fármacos , Femenino , Humanos , Células MCF-7 , Transducción de Señal/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacosRESUMEN
BACKGROUND: To observe the inhibition effects of the Buthus matensii Karsch (BmK) scorpion venom extracts on the growth of human breast cancer MCF-7 cells, and to explore its mechanisms. METHODS: Two common tumor cells (SMMC7721, MCF-7) were examined for the one which wasmore sensitivity to scorpion venom by MTT method. Cell cycle was determined by flow cytometry. Immunocytochemistry was applied to detect apoptosis-related protein Caspase-3 and Bcl-2 levels, while the expression of cell cycle-related protein Cyclin D1 was shown by Western blotting. RESULTS: Our data indicated that MCF-7 was the more sensitive cell line to scorpion venom. The extracts of scorpion venom could inhibit the growth and proliferation of MCF-7 cells. Furthermore, the extract of scorpion venom induced apoptosis through Caspase-3 up-regulation while Bcl-2 down-regulation in MCF-7 cells. In addition, the extracts of scorpion venom blocked the cells from G0/G1 phase to S phase and decreased cell cycle-related protein Cyclin D1 level after drug intervention compared with the negative control group. CONCLUSIONS: These results showed that the BmK scorpion venom extracts could inhibit the growth of MCF-7 cells by inducing apoptosis and blocking cell cycle in G0/G1 phase. The BmK scorpion venom extracts will be very valuable for the treatment of breast cancer.
Asunto(s)
Antineoplásicos/uso terapéutico , Productos Biológicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Ciclo Celular/efectos de los fármacos , Venenos de Escorpión/uso terapéutico , Escorpiones , Animales , Antineoplásicos/farmacología , Apoptosis , Productos Biológicos/farmacología , Neoplasias de la Mama/metabolismo , Caspasa 3/metabolismo , Proliferación Celular , Ciclina D1/metabolismo , Regulación hacia Abajo , Femenino , Humanos , Células MCF-7 , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Venenos de Escorpión/farmacologíaRESUMEN
AIM: To elucidate the roles of receptor tyrosine kinases RET and VEGFR2 and the RAF/MEK/ERK signaling cascade in cancer treatment with sorafenib. METHODS: The cell lines A549, HeLa, and HepG2 were tested. The enzyme activity was examined under cell-free conditions using 384-well microplate assays. Cell proliferation was evaluated using the Invitrogen Alarmar Blue assay. Gene expression was analyzed using the Invitrogen SYBR Green expression assays with a sequence detection system. Protein expression analysis was performed using Western blotting. RESULTS: Sorafenib potently suppressed the activities of cRAF, VEGFR2, and RET with IC(50) values of 20.9, 4 and 0.4 nmol/L, respectively. Sorafenib inhibited cRAF, VEGFR2, and RET via non-ATP-competitive, ATP-competitive and mixed-type modes, respectively. In contrast, sorafenib exerted only moderate cytotoxic effects on the proliferation of the 3 cell lines. The IC(50) values for inhibition of A549, HeLa, and HepG2 cells were 8572, 4163, and 8338 nmol/L, respectively. In the 3 cell lines, sorafenib suppressed the cell proliferation mainly by blocking the MEK/ERK downstream pathway at the posttranscriptional level, which in turn regulated related gene expression via a feed-back mechanism. CONCLUSION: This study provides novel evidence that protein kinases RET and VEGFR2 play crucial roles in cancer treatment with sorafenib.
Asunto(s)
Antineoplásicos/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Neoplasias/tratamiento farmacológico , Niacinamida/análogos & derivados , Compuestos de Fenilurea/farmacología , Proteínas Proto-Oncogénicas c-ret/antagonistas & inhibidores , Receptor 2 de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Antineoplásicos/uso terapéutico , Western Blotting , Técnicas de Cultivo de Célula , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Sistema de Señalización de MAP Quinasas/genética , Neoplasias/enzimología , Neoplasias/patología , Niacinamida/farmacología , Niacinamida/uso terapéutico , Compuestos de Fenilurea/uso terapéutico , Proteínas Proto-Oncogénicas c-ret/genética , Interferencia de ARN/efectos de los fármacos , Reacción en Cadena en Tiempo Real de la Polimerasa , Sorafenib , Receptor 2 de Factores de Crecimiento Endotelial Vascular/genéticaRESUMEN
OBJECTIVE: To observe the potential effect of tea polyphenols and EGCG on cultured hypertrophic myocyte induced by Ang II. METHODS: The study used cultured neonatal rat myocytes as a model to observe the potential effects of 10 microg/ml, 50 microg/ml and 100 microg/ml tea polyphenols and EGCG on hypertrophic myocyte induced by Ang II. We will measure the protein contents, the volume of myocyte, the numbers of fibrocasts. RESULT: When compared to control group (untreated), the protein contents, the volume of myocytes, the numbers of fibrocasts in Ang II group increased. But all those in tea polyphenols and EGCG group decreased in a dose-dependent manner, when compared to Ang II group. However, the number of the myocyte cells in all groups has no significantly changed. CONCLUSIONS: Tea polyphenols and EGCG can effectively inhibit hypertrophy of cultured neonatal rat heart myocytes induced by Ang II.
Asunto(s)
Cardiomegalia/prevención & control , Catequina/análogos & derivados , Flavonoides/farmacología , Miocitos Cardíacos/patología , Fenoles/farmacología , Té/química , Angiotensina II/farmacología , Animales , Animales Recién Nacidos , Cardiomegalia/inducido químicamente , Cardiomegalia/patología , Catequina/aislamiento & purificación , Catequina/farmacología , Células Cultivadas , Femenino , Flavonoides/aislamiento & purificación , Masculino , Fenoles/aislamiento & purificación , Polifenoles , Ratas , Ratas WistarRESUMEN
OBJECTIVE: To investigate the preventive effects and the molecular mechanism of tea and tea extracts (polyphenols and EGCG) on left ventricle hypertrophy (LVH) induced by Renovascular hypertension in rats. METHODS: One hundred and sixty male Wistar rats were randomly divided into five groups: negative control group (SHAM), operation group (2K1C), green tea group (2K1C + GT), tea polyphenol group (2K1C + TP), EGCG group (2K1C + EGCG). After surgery operation, rats in different groups received tap water, tap water, 2% green tea, 0.1% tea polyphenol and 0.05% EGCG respectively, as the sole drinking source for 8 weeks until the end of the experiment. RESULTS: The results showed that the blood pressure, the ratio of left ventricle weight to body weight (LVW/BW) and the left ventricular wall thicknesses (LVWT) in 2K1C group significantly increased (P < 0.01), when compared to those in sham operation group. However, when compared to these parameters in operation group, the ratio of LVW/BW and HW/BW in green tea group, tea polyphenols group and EGCG group significantly decreased (P < 0.05), while the activities of GSH-Px and SOD increased, and the levels of ROS in heart were also significantly decreased (P < 0.05). Ras, P-ERK protein expressions in tea-treatment groups were also decreased. CONCLUSION: Green tea, tea polyphenols and EGCG can attenuate the development of left ventricular hypertrophy induced by renal hypertension in rats. The possible mechanisms may be due to its antioxidant properties and the modulation of Ras-to-MAPKs mediated signal transduction.
Asunto(s)
Antioxidantes/farmacología , Flavonoides/farmacología , Hipertensión Renovascular/complicaciones , Hipertrofia Ventricular Izquierda/prevención & control , Fenoles/farmacología , Té/química , Animales , Catequina/análogos & derivados , Catequina/aislamiento & purificación , Catequina/farmacología , Flavonoides/aislamiento & purificación , Hipertensión Renovascular/fisiopatología , Hipertrofia Ventricular Izquierda/etiología , Hipertrofia Ventricular Izquierda/fisiopatología , Masculino , Fenoles/aislamiento & purificación , Polifenoles , Distribución Aleatoria , Ratas , Ratas WistarRESUMEN
AIM: To screen antifungal drug candidates using in vitro and in vivo assays based on type I methionine aminopeptidase from Saccharomyces cerevisiae (ScMetAP1). METHODS: A colorimetric assay suitable for high throughput screening (HTS) using recombinant ScMetAP1 protein expressed in Escherichia coli was established for antifungal lead discovery. A series of pyridine-2-carboxylic acid derivatives were characterized and a chemical library of 12,800 pure organic compounds was screened with the in vitro ScMetAP1 assay. Active compounds from the in vitro assay were further evaluated by a growth inhibition assay on yeast strain with deletion of ScMetAP1 gene map1 in comparison with the wild-type yeast strain and the yeast strain with deletion of type II enzyme (ScMetAP2) gene map2. RESULTS: Active ScMetAP1 inhibitors were identified from HTS. Some of the pyridine-2-carboxylic acid derivatives (compound 2 and 3) had selective inhibition of the growth of map2 deletion yeast and weak inhibition on wild-type yeast growth, while no inhibition on map1 deletion yeast. CONCLUSION: ScMetAP1 is a novel potential target for developing antifungal drugs. The in vitro and in vivo ScMetAP1 assays can serve as tools in discovering antifungal drug candidates.